Maternal RSV vaccine held about 80% protection in real-world infants, while nirsevimab's benefit stayed in year one

The edition in brief

A JAMA Pediatrics meta-analysis of seven real-world studies (7,112 infants in Argentina, the UK and the US) found maternal RSVpreF vaccination at least 14 days before delivery was 82% effective against RSV lower respiratory tract infection admission in the first 3 months and 78% to 6 months. Two French nationwide matched cohorts (about 250,000 infants) found nirsevimab was 66–72% effective against RSV admission in the first year, with no protection in the second year, and observed higher rates of admission for bacterial ear, nose and throat infections and, in year two, asthma — associations of uncertain meaning. A French trial of 103 infants with bronchiolitis found automated closed-loop oxygen kept saturations in range more of the time with lower flows, but did not shorten admission. A Norwegian cohort of 747 children linked a parent's smartphone time, rather than the child's own screen time, to slower vocabulary growth from 5 to 7. The pearl covers oxygen targets in bronchiolitis.